4,10,13-trimethyl-17-(6-methyl-5-methylideneheptan-2-yl)-2,3,4,5,6,7,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4,10,13-trimethyl-17-(6-methyl-5-methylideneheptan-2-yl)-2,3,4,5,6,7,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
• 化学式: C₂₉H₄₆O
• 分子量: 410.7
• InChiKey: HLAWVOWADPNAGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Compositions And Methods To Treat And/Or Prevent Vision Disorders Of The Lens Of The Eye
  申请人：Helix Holding Company

  公开号：US20190117675A1

  公开（公告）日：2019-04-25

  The disclosure generally relates to compositions and uses thereof to treat vision disorders that affect the normal function of the lens in the eye in a subject having or at risk of developing such vision disorders.
• [EN] COMPOSITIONS AND METHODS TO TREAT AND/OR PREVENT VISION DISORDERS OF THE LENS OF THE EYE<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER ET/OU PRÉVENIR DES TROUBLES DE LA VISION DU CRISTALLIN DE L'OEIL
  申请人：ZHANG KANG

  公开号：WO2016029197A1

  公开（公告）日：2016-02-25

  The disclosure generally relates to compositions and uses thereof to treat vision disorders that affect the normal function of the lens in the eye in a subject having or at risk of developing such vision disorders.